Detecting spinal cord lesions in multiple sclerosis using advanced MRI techniques
Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences: A Pilot Study
NA · University Hospital, Basel, Switzerland · NCT04819737
This study is testing a new MRI technique to see if it can better detect spinal cord lesions in people with multiple sclerosis.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland (other) |
| Locations | 1 site (Basel) |
| Trial ID | NCT04819737 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a novel MRI sequence called averaged magnetization inversion recovery acquisitions (AMIRA) for detecting spinal cord lesions in patients with multiple sclerosis. The research focuses on assessing the sensitivity of this imaging technique and the agreement between different observers in identifying lesions. Additionally, it aims to determine the clinical value of AMIRA in real-world settings, leveraging its superior contrast and resolution for better diagnosis. Participants will undergo spinal cord MRI and complete a patient questionnaire as part of the evaluation process.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with multiple sclerosis who meet specific inclusion criteria and are part of the Swiss MS Cohort.
Not a fit: Patients with severe neurological, internal, or psychiatric diseases affecting the spinal cord, or those with contraindications for MRI, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved detection of spinal cord lesions in multiple sclerosis, enhancing diagnosis and treatment planning.
How similar studies have performed: Other studies have shown promise in using advanced MRI techniques for detecting lesions in multiple sclerosis, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of multiple sclerosis according to established international criteria * Steroid free period: \> 4 weeks * Participation in the Swiss MS Cohort (SMSC) study Exclusion Criteria: * . History of severe (other) neurological, internal or psychiatric disease with SC affection * MRI-related exclusion criteria (questionnaire): 1. Paramagnetic and/or superparamagnetic foreign objects in the body (especially when located close to the SC) 2. Pacemaker 3. Claustrophobia 4. Pregnancy, lactation 5. Known hypersensitivity to gadolinium-based contrast media
Where this trial is running
Basel
- University Hospital Basel, Department of Neurology — Basel, Switzerland (RECRUITING)
Study contacts
- Principal investigator: Katrin Parmar, PD Dr. med. — University Hospital Basel, Department of Neurology
- Study coordinator: Katrin Parmar, PD Dr. med.
- Email: katrin.parmar@unibas.ch
- Phone: +41 61 83 65 214
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Sclerosis, spinal cord pathology, demyelinating lesions, Spinal cord MRI, Averaged magnetization inversion recovery acquisitions sequence, Swiss MS Cohort